MX 28701

Drug Profile

MX 28701

Alternative Names: MX 2870 1

Latest Information Update: 14 Oct 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 14 Oct 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 30 Apr 2003 Incyte Genomics is now called Incyte Corporation
  • 03 Mar 2003 Maxia Pharmaceuticals has been acquired by Incyte Genomics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top